Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Bayer AG
Deal Size : $1,300.0 million
Deal Type : Collaboration
Bayer and Kumquat Biosciences Enter Global License and Collaboration in Precision Oncology
Details : The collaboration focuses on developing a KRAS G12D inhibitor, complementing Bayer’s precision oncology development portfolio in the areas of pancreatic, colorectal and lung cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Bayer AG
Deal Size : $1,300.0 million
Deal Type : Collaboration
KQB168 Safety and Efficacy Monotherapy/Combo In Advanced Solid Tumors
Details : KQB168 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2025
Details : KQB365 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 06, 2024
Details : KQB198 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 17, 2024
Details : KQB198 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $1,330.0 million
Deal Type : Collaboration
Kumquat Biosciences Partners with Takeda On Oral Immuno-Oncology Drug
Details : Kumquat granted Takeda a global license to develop and commercialize a novel immuno-oncology small molecule inhibitor as a mono- or combination-therapy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $130.0 million
April 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $1,330.0 million
Deal Type : Collaboration
Lilly and Kumquat Biosciences Discover and Develop Novel Small Molecules
Details : Kumquat will utilize its small molecule immuno-oncology platform to discover novel clinical candidates and Lilly has the option to select a certain number of drug candidates for further development and commercialization worldwide, excluding Greater China...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $70.0 million
July 29, 2021